PMID- 26315074
OWN - NLM
STAT- MEDLINE
DCOM- 20160418
LR  - 20181113
IS  - 2542-5641 (Electronic)
IS  - 0366-6999 (Print)
IS  - 0366-6999 (Linking)
VI  - 128
IP  - 17
DP  - 2015 Sep 5
TI  - Pediatric Heart Transplantation: Report from a Single Center in China.
PG  - 2290-4
LID - 10.4103/0366-6999.163396 [doi]
AB  - BACKGROUND: Although heart transplantation (HTx) has become a standard therapy 
      for end-stage heart diseases, experience with pediatric HTx is limited in China. 
      In this article, we will try to provide the experience with indications, 
      complications, perioperative management, immunosuppressive therapy, and survival 
      for pediatric HTx based on our clinical work. METHODS: This is a retrospective 
      chart review of the pediatric patients undergoing HTx at Department of 
      Cardiovascular Surgery of Union Hospital from September 2008 to December 2014. We 
      summarized the indications, surgical variables, postoperative complications, and 
      survival for these patients. RESULTS: Nineteen pediatric patients presented for 
      HTx at Union Hospital of Tongji Medical College, of whom 10 were male. The age at 
      the time of transplantation ranged from 3 months to 18 years (median 15 years). 
      Patient weight ranged from 5.2 kg to 57.0 kg (median 38.0 kg). Pretransplant 
      diagnosis included cardiomyopathy (14 cases), complex congenital heart disease (3 
      cases), and tumor (2 cases). All recipients received ABO-compatible donor hearts. 
      Postoperative complications occurred in 12 patients, including cardiac 
      dysfunction, arrhythmia, pulmonary infection, renal dysfunction, and rejection. 
      Two of them experienced cardiac failure and required extracorporeal membrane 
      oxygenation. The immunosuppression regimen was comprised of prednisone, a 
      calcineurin inhibitor, and mycophenolate. All patients recovered with New York 
      Heart Association (NYHA) Class I-II cardiac function and were discharged. Only 
      one patient suffered sudden death 19 months after transplantation. CONCLUSION: 
      Orthotopic HTx is a promising therapeutic option with satisfying survival for the 
      pediatric population in China with end-stage heart disease.
FAU - Li, Fei
AU  - Li F
FAU - Cai, Jie
AU  - Cai J
FAU - Sun, Yong-Feng
AU  - Sun YF
FAU - Liu, Jin-Ping
AU  - Liu JP
FAU - Dong, Nian-Guo
AU  - Dong NG
AD  - Department of Cardiovascular Surgery, Union Hospital, Tongji Medical College, 
      Huazhong University of Science and Technology, Wuhan, Hubei 430022, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - China
TA  - Chin Med J (Engl)
JT  - Chinese medical journal
JID - 7513795
RN  - 0 (Immunosuppressive Agents)
SB  - IM
MH  - Adolescent
MH  - Child
MH  - China
MH  - Female
MH  - Heart Transplantation/*statistics & numerical data
MH  - Humans
MH  - Immunosuppressive Agents/therapeutic use
MH  - Infant
MH  - Male
MH  - Retrospective Studies
MH  - Treatment Outcome
PMC - PMC4733789
EDAT- 2015/09/01 06:00
MHDA- 2016/04/19 06:00
PMCR- 2015/09/05
CRDT- 2015/08/29 06:00
PHST- 2015/08/29 06:00 [entrez]
PHST- 2015/09/01 06:00 [pubmed]
PHST- 2016/04/19 06:00 [medline]
PHST- 2015/09/05 00:00 [pmc-release]
AID - ChinMedJ_2015_128_17_2290_163396 [pii]
AID - CMJ-128-2290 [pii]
AID - 10.4103/0366-6999.163396 [doi]
PST - ppublish
SO  - Chin Med J (Engl). 2015 Sep 5;128(17):2290-4. doi: 10.4103/0366-6999.163396.